A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.

被引：0
|
作者：
Dumbrava, Ecaterina Elena
Kennon, Amber Michelle
Balema, Wintana A.
Lim, Chaemin
Vempati, Sridhar
Stergiopoulos, Sotirios
Richardson, Debra L.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[2] A2A Pharmaceut Inc, New York, NY USA
[3] Univ Oklahoma, Div Gynecol Oncol, Stephenson Canc Ctr, Hlth Sci Ctr, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3176
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
    Mehra, Ranee
    Camidge, D. Ross
    Sharma, Sunil
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    De Pas, Tommaso Martino
    Kim, Dong-Wan
    Santoro, Armando
    Liu, Geoffrey
    Goldwasser, Meredith
    Dai, David
    Radona, Marietta
    Boral, Anthony
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.
    Perets, Ruth
    Geva, Ravit
    McKean, Meredith
    Goutopoulos, Andreas
    Erez, Omri
    Phadnis, Monica
    Youssoufian, Hagop
    Schwartz, Brian E.
    Kansra, Vikram
    Fattaey, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] First-in-human phase I study of an oral HSP9O inhibitor, TAS-116, in advanced solid tumors.
    Yanagitani, Noriko
    Horiike, Atsushi
    Kitazono, Satoru
    Ohyanagi, Fumiyoshi
    Kondo, Shunsuke
    Shimomura, Akihiko
    Fujiwara, Yutaka
    Doi, Toshihiko
    Kuboki, Yasutoshi
    Kawazoe, Akihito
    Shitara, Kohei
    Ohno, Izumi
    Banerji, Udai
    Sundar, Raghav
    Ohkubo, Shuichi
    Huang, Jerry M.
    Nishio, Makoto
    Yamamot, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors.
    Matsubara, Nobuaki
    Shitara, Kohei
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ohno, Izumi
    Takahashi, Hideaki
    Bando, Hideaki
    Kojima, Takashi
    Fuse, Nozomu
    Yamazaki, Tomoko
    Hirayama, Naoki
    Fujita, Hidenori
    Nishida, Toshirou
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
    Stein, Mark N.
    Mayer, Tina M.
    Moss, Rebecca Anne
    Silk, Ann W.
    Chan, Nancy
    Haffty, Bruce George
    DiPaola, Robert S.
    Beckett, Yasmeen
    Bentlyewski, Edward
    Zheng, Ling
    Fang, Bruno
    Allen, Joshua
    Mehnert, Janice M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Shen, Lin
    Gong, Jifang
    Huang, Cheng
    Ye, Chen Yang
    Yang, Li
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Patel, Manish R.
    Yap, Timothy A.
    McEachern, Kristen
    Kuplast-Barr, Kristy
    Utley, Luke
    Cleary, Lisa
    Manyak, Erika
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Liang, Yan
    Harvey, R. Donald
    Fu, Siqing
    Weitao, Yao
    Qin, Yan-Ru
    Zhang, Xiaojing
    Henry, Jason Timothy
    Zou, Qingping
    Shan, Boyao
    Liang, Pan
    Wang, Chen
    Li, Wenjia
    Pamuklar, Zehra Nurgul
    Pei, Yi
    Chang, Zhiwei
    Wang, Jiaqiang
    Piha-Paul, Sarina A.
    Bhave, Manali A.
    Yin, Yongmei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pis) with advanced solid tumors.
    Kumar, Rajiv
    Mateo, Joaquin
    Smith, Alan D.
    Khan, Khurum Hayat
    Ruddle, Ruth
    Swales, Karen E.
    Decordova, Shaun
    Backholer, Zoe
    Jones, Paul
    Tran, Christine
    Seeramraddi, Satyanarayana
    McLeod, Robert
    Yap, Timothy Anthony
    Raynaud, Florence I.
    Garrett, Michelle D.
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345